Collegium Pharmaceutical Crecimiento futuro

Future controles de criterios 4/6

Se prevé que los ingresos de Collegium Pharmaceutical disminuyan en un 6.8% al año, mientras que se espera que sus beneficios anuales crezcan en un 25.4% al año. Se prevé que el BPA crezca en un 23% anual. Se prevé que la rentabilidad financiera sea de 41.6% en 3 años.

Información clave

25.4%

Tasa de crecimiento de los beneficios

23.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.9%
Tasa de crecimiento de los ingresos	-6.8%
Rentabilidad financiera futura	41.6%
Cobertura de analistas	Good
Última actualización	27 Mar 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12

There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding

Feb 15

We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt

Oct 30

Sizing Up Collegium Pharmaceuticals

Oct 04

Collegium Pharmaceutical: Moving Closer To The Top

Jul 12

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment

May 14

Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings

May 13

We Think Collegium Pharmaceutical (NASDAQ:COLL) Is Taking Some Risk With Its Debt

May 01

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:COLL - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	565	174	N/A	340	5
12/31/2025	596	144	311	328	6
12/31/2024	584	116	292	346	6
12/31/2023	567	48	274	275	N/A
9/30/2023	547	9	266	268	N/A
6/30/2023	537	-11	235	236	N/A
3/31/2023	525	-29	176	177	N/A
12/31/2022	464	-25	123	124	N/A
9/30/2022	362	-43	93	94	N/A
6/30/2022	314	-35	67	69	N/A
3/31/2022	273	43	56	58	N/A
12/31/2021	277	72	102	104	N/A
9/30/2021	326	104	87	90	N/A
6/30/2021	326	107	102	107	N/A
3/31/2021	321	42	115	121	N/A
12/31/2020	310	27	-280	94	N/A
9/30/2020	308	18	-286	87	N/A
6/30/2020	302	0	-313	59	N/A
3/31/2020	299	-13	-341	30	N/A
12/31/2019	297	-23	21	28	N/A
9/30/2019	296	-11	47	54	N/A
6/30/2019	293	-22	81	90	N/A
3/31/2019	291	-30	123	131	N/A
12/31/2018	280	-39	145	169	N/A
9/30/2018	218	-66	91	114	N/A
6/30/2018	160	-62	39	59	N/A
3/31/2018	90	-70	-34	-14	N/A
12/31/2017	28	-75	-68	-67	N/A
9/30/2017	19	-85	N/A	-77	N/A
6/30/2017	7	-98	N/A	-84	N/A
3/31/2017	4	-102	N/A	-87	N/A
12/31/2016	2	-94	N/A	-75	N/A
9/30/2016	0	-76	N/A	-61	N/A
6/30/2016	N/A	-59	N/A	-48	N/A
3/31/2016	N/A	-40	N/A	-31	N/A
12/31/2015	N/A	-20	N/A	-22	N/A
9/30/2015	N/A	-15	N/A	-20	N/A
6/30/2015	N/A	-13	N/A	-18	N/A
3/31/2015	N/A	-12	N/A	-16	N/A
12/31/2014	N/A	-21	N/A	-18	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (25.4% al año) de COLL es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (25.4% al año) de COLL crezcan más rápidamente que el mercado US (14.7% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de COLL crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de COLL disminuyan en los próximos 3 años (-6.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de COLL disminuyan en los próximos 3 años (-6.8% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de COLL sea muy elevada dentro de 3 años (41.6%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Collegium Pharmaceutical Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target increased by 13% to US$37.75

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Price target decreased by 8.3% to US$33.25

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

Recent updates

Collegium Pharmaceutical, Inc., Annual General Meeting, May 16, 2024

Investor sentiment improves as stock rises 15%

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Collegium Pharmaceutical Q4: The Beat Goes On

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Full year 2023 earnings: EPS exceeds analyst expectations

Collegium Pharmaceutical, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Executive VP & Chief Commercial Officer notifies of intention to sell stock

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Price target increased by 13% to US$37.75

President notifies of intention to sell stock

Executive VP exercised options and sold US$253k worth of stock

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

Collegium Pharmaceutical, Inc. Revises Earnings Guidance for the Full-Year of 2023

New minor risk - Shareholder dilution

Collegium Pharmaceutical, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Collegium Pharmaceutical, Inc. Announces Extension of Nucynta Regulatory Exclusivity Through July 2026

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Year 2023

Collegium Pharmaceutical, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Price target decreased by 8.3% to US$33.25

Executive VP notifies of intention to sell stock

President notifies of intention to sell stock

Collegium Pharmaceutical, Inc. Reaffirms Product Revenues Guidance for Full-Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP & CFO notifies of intention to sell stock

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Executive VP & Chief Commercial Officer notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 12% to US$36.00

Executive VP notifies of intention to sell stock

Collegium Pharmaceutical, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Price target increased to US$34.00

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2023

Co-Founder & Chairman notifies of intention to sell stock

Appeals Court Affirms Validity of Collegium's Belbuca(R) Patents

Co-Founder & Chairman exercised options and sold US$1.3m worth of stock

President notifies of intention to sell stock

Insufficient new directors

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year of 2022

Third quarter 2022 earnings released: EPS: US$0.013 (vs US$0.23 in 3Q 2021)

Collegium Pharmaceutical, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Executive VP & CFO notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to US$31.40

Collegium Pharmaceutical, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Consensus forecasts updated

Investor sentiment improved over the past week

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Collegium Pharmaceutical, Inc. Appoints Neil McFarlane to its Board of Directors

Consensus EPS estimates fall by 16%

Collegium Pharmaceutical, Inc. Provides Revenue Guidance for the Year 2022

Collegium Pharmaceutical, Inc. Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Collegium Pharmaceutical, Inc. Provides Earnings Guidance for the Year 2022

Price target increased to US$27.71

Collegium Pharmaceutical: Thoughts After Another Strategic Move

Collegium Pharmaceutical, Inc. (NasdaqGS:COLL) entered into an agreement to acquire BioDelivery Sciences International, Inc. (NasdaqGS:BDSI) for approximately $580 million.

Investor sentiment improved over the past week